Bread can vary in textural and nutritional attributes based on differences in the bread making process (e.g., flour type, fermentation agent, fermentation time). Four bread recipes (BRs) made with sourdough preferments (BR1, white flour; BR2, whole grain flour) or regular yeast breads (BR3, white flour; BR4, whole grain flour) were evaluated for texture, digestibility, and their effect on the metabolic activity and composition of the gut microbiota using texture profile analysis (TPA) coupled with in vitro upper gastrointestinal (GIT) digestion and colonic fermentation (Colon-on-a-plate™ model), using fecal samples from eight healthy human donors. TPA revealed significantly higher values for hardness, fracturability, gumminess, and chewiness, and significantly lower values for springiness, cohesiveness, and resilience with whole grain versus white breads (all p < 0.001); values for springiness, cohesiveness, and resilience were significantly higher for sourdough versus yeast bread (p < 0.001). Nutrient composition and bioaccessibility were generally comparable between sourdough and yeast bread with similar flours. Following simulation of upper GIT digestion, all BRs demonstrated good digestibility of minerals, carbohydrates, and proteins. Colonic fermentation revealed changes in gut microbiota composition, significant increases in short-chain fatty acids, and a significant decrease in branched short-chain fatty acids with all BRs versus a blank. Overall, new insights into wheat bread digestibility and colonic fermentation were provided, which are important aspects to fully characterize bread nutritional profile and potential.

Background/Objectives: Post-menopausal women are at an increased risk of developing cardiovascular disease. Menaquinone-7 (MK-7) is a fat-soluble vitamin involved in coagulation and maintaining vascular health. The aim of the post hoc analysis of this one-year study is to investigate the effects of MK-7 supplementation on the vascular parameters in pre-, peri-, and post-menopausal women. Methods: In a clinical intervention trial (NCT02404519), a total of 165 women with a low vitamin K status received either 180 µg of MK-7 daily (n = 82) or a matching placebo (n = 83) for one year. Established vascular parameters were measured before and after one year of vitamin K2 supplementation. Pre-, peri-, and post-menopausal women were subdivided according to arterial stiffness, with a high b-stiffness index defined as being greater than the overall median of 9.83. Results: The post hoc analyses showed a significant decrease in desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) plasma levels after MK-7 supplementation (pre/peri, p = 0.009; post, p < 0.001). MK-7 treatment significantly attenuated vascular stiffness in post-menopausal women (placebo +49.1% ± 77.4; MK-7 +9.4% ± 67.1; p = 0.035). Post-menopausal women with a high stiffness index showed significantly improved vascular markers after MK-7 treatment, e.g., a decreased blood pressure at brachialis (−3.0% ± 9.0; p = 0.007) and an increased distensibility coefficient (+13.3% ± 32.3; p = 0.040). Conclusions: Our results confirm that menopause affects vascular health status. Post-menopausal women with an increased stiffness benefit most from MK-7 supplementation, with a significantly improved blood pressure. Further research is needed to unravel the beneficial effects of MK-7 in post-menopausal women.

Background/Objectives: The benefits of vitamin K are well established in skeletal and cardiovascular health through activation of vitamin K-dependent proteins, including osteocalcin and matrix Gla protein. Emerging evidence also links vitamin K to pathways that influence body composition, including insulin sensitivity, adiponectin regulation, lipid oxidation, and inflammation. Vitamin K deficiency is linked to adverse health outcomes. We therefore evaluated whether menaquinone-7 (MK-7) supplementation alters body composition in adults with low vitamin K status. Methods: A total of 243 participants (166 women and 77 men) with low vitamin K status received 180 mcg of menaquinone-7 (MK-7), a form of Vitamin K, daily for one year. Changes in body mass index (BMI), body weight, fat mass, lean mass, and visceral adipose tissue (VAT) were assessed. Results: At baseline, higher dp-ucMGP, indicating lower vitamin K status, was positively associated with BMI (r = 0.223; p < 0.01), fat mass index (r = 0.200; p < 0.01), and VAT (r = 0.286; p < 0.001). After one year of supplementation, the total cohort showed a small but significant BMI reduction (−0.66%; p = 0.041). Responders (≥183 pmol/L dp-ucMGP drop) showed improvements in fat mass (−1.93%, p = 0.039), waist-to-hip ratio (−1.43%, p = 0.012), BMI (−1.37% ± 3.21, p = 0.004), and weight (−1.25%, p = 0.008), while non-responders exhibited an increase in VAT (+7.28%, p = 0.002). Women, especially premenopausal ones, experienced greater reductions in BMI, fat mass, and weight. dp-ucMGP levels significantly decreased in 90.9% of women (p < 0.001), whereas in men, although 77.8% showed a decrease, the change was not statistically significant. Among high responders (≥183 pmol/L dp-ucMGP reduction), both sexes demonstrated improvement, albeit significant body composition changes were seen only in women. Conclusions: Lower vitamin K status was associated with higher BMI, fat mass, and visceral adipose tissue. After one year of MK-7 supplementation, a modest reduction in BMI was observed, with more pronounced improvements in body composition among women. While these sex related differences may suggest that men require higher doses to achieve comparable responses, the current evidence remains preliminary. Further studies with larger cohorts are needed to clarify these findings.